Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacob S Appelbaum

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Blood Neoplasia|August 12, 2025
Treatment discontinuation due to toxicity for patients with acute myeloid leukemia receiving intensive chemotherapySuravi Raychaudhuri, Megan Othus, Mary-Elizabeth M Percival, et al.
JCO Oncology Practice|April 3, 2025
Predictors of Cardiac Recovery in Adults With AML Who Develop Heart Failure During TreatmentMatthew Wu, Kathryn Russell, Carole M Shaw, et al.
Organic Letters|October 4, 2013
A β-peptide agonist of the GLP-1 receptor, a class B GPCRElizabeth V Denton, Cody J Craig, Rebecca L Pongratz, et al.
Blood Advances|October 5, 2024
Identification of factors predicting low-risk febrile neutropenia admissions in adults with acute myeloid leukemiaKhushboo V Pal, Megan Othus, Zahra Ali, et al.
Blood Cancer Journal|January 14, 2024
Time independent factors that predict relapse in adults with acute myeloid leukemiaJohn J Lim, Megan Othus, Carole M Shaw, et al.
Blood Neoplasia|June 19, 2025
Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasmSuravi Raychaudhuri, Ted A Gooley, Allegra Rasmussen, et al.
Cancers|June 24, 2022
Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid NeoplasmsColin D Godwin, Eduardo Rodríguez-Arbolí, Megan Othus, et al.
Blood|May 21, 2026
Chromosome 5q deletion drives evolution of aneuploidy in myeloid neoplasms with complex karyotypeJ Philip Creamer, Suhita Ray, Sintra Stewart, et al.
Blood Advances|June 20, 2023
Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AMLAnna B Halpern, Eduardo Rodríguez-Arbolí, Megan Othus, et al.
Blood|March 11, 2025
Social Determinants of Health and Access to Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid LeukemiaNatalie Wuliji, Salene M W Jones, Ted A Gooley, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Blood Neoplasia|August 12, 2025
Treatment discontinuation due to toxicity for patients with acute myeloid leukemia receiving intensive chemotherapySuravi Raychaudhuri, Megan Othus, Mary-Elizabeth M Percival, et al.
JCO Oncology Practice|April 3, 2025
Predictors of Cardiac Recovery in Adults With AML Who Develop Heart Failure During TreatmentMatthew Wu, Kathryn Russell, Carole M Shaw, et al.
Organic Letters|October 4, 2013
A β-peptide agonist of the GLP-1 receptor, a class B GPCRElizabeth V Denton, Cody J Craig, Rebecca L Pongratz, et al.
Blood Advances|October 5, 2024
Identification of factors predicting low-risk febrile neutropenia admissions in adults with acute myeloid leukemiaKhushboo V Pal, Megan Othus, Zahra Ali, et al.
Blood Cancer Journal|January 14, 2024
Time independent factors that predict relapse in adults with acute myeloid leukemiaJohn J Lim, Megan Othus, Carole M Shaw, et al.
Blood Neoplasia|June 19, 2025
Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasmSuravi Raychaudhuri, Ted A Gooley, Allegra Rasmussen, et al.
Cancers|June 24, 2022
Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid NeoplasmsColin D Godwin, Eduardo Rodríguez-Arbolí, Megan Othus, et al.
Blood|May 21, 2026
Chromosome 5q deletion drives evolution of aneuploidy in myeloid neoplasms with complex karyotypeJ Philip Creamer, Suhita Ray, Sintra Stewart, et al.
Blood Advances|June 20, 2023
Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AMLAnna B Halpern, Eduardo Rodríguez-Arbolí, Megan Othus, et al.
Blood|March 11, 2025
Social Determinants of Health and Access to Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid LeukemiaNatalie Wuliji, Salene M W Jones, Ted A Gooley, et al.
Pageof 3